NAGE vs UCFI
NAGE: A global bioscience company commercializing nicotinamide riboside (Niagen®), a NAD+ precursor, through consumer supplements, pharmaceutical-grade ingredient supply, and clinical research collaborations targeting healthy aging. UCFI: An AI-powered health food technology company blending biotech innovation with traditional Chinese medicine to develop premium nutritional products for the Chinese market.
Side-by-side fundamentals
| Metric | NAGE | UCFI | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.40 | $5.51 | |
| Market cap as of 2026-07-23 | $270M | $288M | |
| P/E as of 2026-07-23 | 14.49 | 66.26 | NAGE lower |
| PEG as of 2026-07-23 | 0.61 | n/a | |
| Net margin as of 2026-07-23 | +14.3% | +30.3% | UCFI higher |
| Gross margin as of 2026-07-23 | +64.3% | +66.3% | UCFI higher |
| Operating margin as of 2026-07-23 | +13.7% | +42.4% | UCFI higher |
| ROE as of 2026-07-23 | +25.4% | +23.0% | NAGE higher |
| ROA as of 2026-07-23 | +18.2% | +8.1% | NAGE higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.18 | NAGE lower |
| Revenue growth (YoY) as of 2026-07-23 | +20.8% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +21.6% | n/a | |
| Beta as of 2026-07-23 | 2.12 | -0.38 | |
| 1-year return as of 2026-07-22 close | -64.1% | -48.5% | UCFI higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.